Stuart Kupfer

22PUBLICATIONS
97CO-AUTHORS
Exercise physiologyPharmacogenomicsToxicology (incl. clinical toxicology)Cardiology (incl. cardiovascular diseases)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Aug 03, 2026
Long-Term Impact of Aficamten on Patient-Reported Outcome Measures in Obstructive Hypertrophic Cardiomyopathy: Results From FOREST-HCM.

|May 08, 2026
Towards a Quantitative Understanding of Aficamten Clinical Pharmacology: Pharmacokinetic-Cardiodynamic Modeling to Support Safety and Efficacy.

|Mar 05, 2026
Clinical Evaluation of Drug-Drug Interactions With Aficamten.

Neha Maharao, Donghong Xu, Punag Divanji

|Mar 04, 2026
Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study.

Albree Tower-Rader, Ahmad Masri, Michael E Nassif

|Mar 02, 2026
Effect of the cardiac myosin activator omecamtiv mecarbil on ventricular arrhythmias, cardiac arrest, and sudden death in heart failure with reduced ejection fraction: the GALACTIC-HF trial.

Alberto Foà, Muthiah Vaduganathan, Brian L Claggett

|Mar 02, 2026
Dipstick proteinuria and outcomes in patients with heart failure and reduced ejection fraction: insights from GALACTIC-HF.

Ryohei Ono, Misato Chimura, Kieran F Docherty

Pageof 4

Frequent Collaborators

10 joint publications

Fady I Malik

9 joint publications

Stephen B Heitner

6 joint publications

Scott D Solomon

6 joint publications

Ahmad Masri